2020 Lung Cancer Updates Spotlight on Clinical Oncology

2020 Lung Cancer Updates Spotlight on Clinical Oncology

moasc

1 month
15 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Sai-Hong Ignatius Ou, MD PhD Health Science Clinical Professor Chao Family Comprehensive Cancer Center University of California Irvine School of Medicine discusses these topics. NSCLC treatment options (circa February 2020 updated May 2020) Targeted therapy (FDA Approved indication) EGFR classical mutations EGFR uncommon mutations ALK fusion ROS1 fusion BRAF V600E METex14+ NSCLC (Approved May 6, 2020) RET fusion (Approved May 8, 2020) Immunotherapy (FDA approved) Chemotherapy + IO for first-line treatment of Non-Sq NSCLC, Sq NSCLC, and SCLC. (PD-L1 expression agnostic) Single agent second line (PD-L1 expression agnostic) Chemotherapy (FDA approved) Chemo + anti-angiogenesis mAb (non-Sq NSCLC) Chemo + anti EGFR mAb (Sq NSCLC) Single agent + anti-angiogenesis mAb
Up Next Autoplay